Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;46(1):36-42.
doi: 10.3164/jcbn.09-48. Epub 2009 Dec 29.

Retinol supplements antiviral action of interferon in patients with chronic hepatitis C: a prospective pilot study

Naruaki Kohge  1 , Shuichi Sato, Sachiko Hamamoto, Shuji Akagi, Yasushi Uchida, Tatsuya Miyake, Tomoko Mishiro, Kohichiro Furuta, Naoki Oshima, Junnichi Ishine, Yoshiko Takahashi, Norihisa Ishimura, Ryo Fukuda, Shunji Ishihara, Yuji Amano, Yoshikazu Kinoshita
Affiliations

Retinol supplements antiviral action of interferon in patients with chronic hepatitis C: a prospective pilot study

Naruaki Kohge et al. J Clin Biochem Nutr. 2010 Jan.

Abstract

Sustained virologic response with peg-interferon and ribavirin combination therapy for 48 weeks is still inadequate. Our study examined whether short-term administration of retinol clinically influences the anti-viral activity of interferon early during interferon and ribavirin combination therapy. The control group received 6 MIU of interferon alpha-2b every day for two weeks and then 3 times a week for 22 weeks intramuscularly plus 600 mg or 800 mg per day of ribavirin orally for 24 weeks. The retinol group, in addition to above treatment, received retinol 30,000 units per day orally for 3 weeks from one week before the start of interferon alpha-2b plus ribavirin combination therapy. The hepatitis C virus (HCV) RNA negativity rate at 1 week after the end of interferon alpha-2b and ribavirin combination therapy was 46.7% (28/60) for the retinol group and 31.7% (19/60) for the control group, which was significantly higher for the retinol group. The level of serum HCV RNA in the retinol group was significantly lower at 1 week after beginning treatment as compared to the control group (p<0.01). Furthermore, serum 2,5'AS protein at 1 week after beginning treatment was significantly higher in the retinol group (p = 0.0002). The results suggest that retinol supplement increases the antiviral effect of interferon alpha-2b plus ribavirin only during the administration of IFN alpha-2b, ribavirin and retinol in patients with chronic hepatitis C.

Keywords: chronic hepatitis; hepatitis C; retinol; ribavirin; virological response.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Serum retinol concentration before and 1, 2, and 4 weeks after the start of retinol administration. Open circle shows serum concentration with control group, and closed circle shows that with retinol group. *p<0.05, **p = 0.002.
Fig. 2
Fig. 2
Changes in serum HCV-RNA levels. Closed circles showed HCV-RNA levels in the retinol group and open circles those in the control group. Data are expressed as the mean ± standard error (SE). **p<0.01; Mann-Whitney U test.
Fig. 3
Fig. 3
Serum 2,5'AS protein concentration one week after IFN α-2b plus ribavirin combination therapy. Data are expressed as mean ± standard error (SE).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., Buggisch P., Goeser T., Rasenack J., Pape G.R., Schmidt W.E., Kallinowski B., Klinker H., Spengler U., Martus P., Alshuth U., Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086–1097. - PubMed
    1. Taliani G., Gemignani G., Ferrari C., Aceti A., Bartolozzi D., Blanc P.L., Capanni M., Esperti F., Forte P., Guadaqnino V., Mari T., Marino N., Milani S., Pasquazzi C., Rosina F., Tacconi D., Toti M., Ziqnego A.L., Messerini L., Stroffolini T. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology. 2006;130:1098–1106. - PubMed
    1. Jacobson I.M., Gonzalez S.A., Ahmed F., Lebovics E., Min A.D., Bodenheimer H.C. Jr., Esposito S.P., Brown R.S. Jr., Brau N., Klion F.M., Tobias H., Bini E.J., Brodsky N., Cerulli M.A., Aytaman A., Gardner P.W., Geders J.M., Spivack J.E., Rahmin M.G., Berman D.H., Ehrlich J., Russo M.W., Chait M., Rovner D., Edlin B.R. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am. J. Gastroenterol. 2005;100:2453–2462. - PubMed
    1. Huber M., Weber R., Oppliger R., Vernazza P., Schmid P., Schonbucher P., Bertisch B., Meili D., Renner E.L. Interferon alpha-2a Plus Ribavirin 1,000/1,200 mg versus Interferon alpha-2a Plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treat. Infection. 2005;33:25–29. - PubMed
    1. Lindahl K., Stahle L., Bruchfeld A., Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology. 2005;41:234–236. - PubMed